Sanofi opens $925M flu vaccine facility in Toronto, marking Canada’s largest bio-manufacturing investment
Sanofi has officially opened a massive new flu‑vaccine manufacturing facility in Toronto — a $925‑million project billed as the largest single bio-manufacturing investment in Canadian history. The Charles Best Building, located on Sanofi’s 52‑acre Toronto campus, will produce Fluzone High‑Dose, a high‑potency influenza vaccine designed for adults 65 and older, who account for the majority […]
Sanofi has inaugurated a $925 million flu vaccine manufacturing facility in Toronto, marking Canada's largest single bio-manufacturing investment ever. The Charles Best Building, situated on a 52-acre campus, will produce Fluzone High-Dose, a high-potency influenza vaccine tailored for adults aged 65 and above, who are disproportionately affected by flu-related hospitalizations.
This expansion not only enhances Canada's industrial-scale vaccine production capabilities but also bolsters the nation's preparedness for future flu pandemics. Federal and provincial governments contributed $415 million and $55 million respectively to the project. The facility, which has been under construction since 2021, is now fully operational and expected to commence production in early 2027 for the upcoming flu season.
Upon receiving regulatory approval, Sanofi anticipates the facility to generate approximately 300 highly skilled bio-manufacturing jobs. Presently, the company distributes vaccines produced in Toronto to over 60 countries globally.
Written by urgent.news from CityNews's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
